2024-03-01 05:40:38
The CEO of Novo NordiskLars Fruergaard Jorgensen, believes that to “make a dent” in a condition like obesity, the company needs to treat many more patients than those who were already receiving treatment currently.
To this end, he states that the company would be willing to be “flexible” in pricing plans so that it is possible to adopt medications in advance, see the benefitss, and pay later.
Although the Danish company does not plan to reduce the price of the treatment, despite the competition that might result from Eli Lilly’s ‘Zepbound’ drug, the manager does express the willingness to share the cost.
“How can health systems justify a large one-time payment up front that will generate significant savings in the future? “I think we need to share that risk to move forward.”
In this way, providers of medical attention might spread the cost over a longer period during which savings might be achieved, for example by not having to treat as many costly heart attacks, as recent trial data showed that Wegs reduced the risk of serious cardiac events by approximately 20%.
1709309829
#Novo #Nordisk #studies #flexible #prices #Wegovy #antiobesity #drug
